World Health Organization (2023) Hepatitis B. World Health Organization website. https://www.who.int/zh/news-room/fact-sheets/detail/hepatitis-b. Accessed 18 Nov 2023

Xu Y, Liu Y, Zhao M, Chen Y, Xie C, Gong M, Deng H, Li X, Sun J, Hou J, Wu H, Wang Z (2017) Dynamic perturbations of CD4 and CD8 T cell receptor repertoires in chronic hepatitis B patients upon oral antiviral therapy. Front Immunol 8:1142. https://doi.org/10.3389/fimmu.2017.01142

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang X, Li J, Liu J, Gao M, Zhou L, Lu W (2017) Relationship of Treg/Th17 balance with HBeAg change in HBeAg-positive chronic hepatitis B patients receiving telbivudine antiviral treatment: a longitudinal observational study. Medicine (Baltimore) 96(23):e7064. https://doi.org/10.1097/MD.0000000000007064

Article  CAS  PubMed  Google Scholar 

Liu B, Shen B, Mei M, Li L, Wang X, Zhao H (2020) Potential effects of telbivudine versus entecavir on renal function in patients with chronic hepatitis B virus receiving Glucocorticoids Therapy. Ther Apher Dial 24(1):56–63. https://doi.org/10.1111/1744-9987.12839

Article  CAS  PubMed  Google Scholar 

Yu HC, Lin KH, Tsay FW, Tsai TJ, Wu PC, Chen YH, Chen YH (2020) Kinetics of hepatitis B surface antigen and estimated glomerular filtration rate in telbivudine-treated hepatitis B patients with different rescue strategies. PLoS ONE 15(8):e0237586. https://doi.org/10.1371/journal.pone.0237586

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Y, Chen W, Jin C, Wang T, Yao T, Feng S, Wang B, Feng Y, Wang S (2022) Infant immune response to hepatitis B vaccine after fetal exposure to telbivudine. Hum Vaccin Immunother 18(1):2029259. https://doi.org/10.1080/21645515.2022.2029259

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiang H, Ye X, Chen C, Zhou G, Han G (2023) Efficacy and long-term safety of telbivudine usage during second or third trimester in hepatitis B surface antigen positive mothers with high viral load: a 10-year prospective study. J Clin Gastroenterol 57(4):423–428. https://doi.org/10.1097/MCG.0000000000001779

Article  CAS  PubMed  Google Scholar 

Xing T, Xu H, Cao L, Ye M (2017) HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term nucleos(t)ide analog treatment: a systematic review and network meta-analysis. PLoS ONE 12(1):e0169444. https://doi.org/10.1371/journal.pone.0169444

Article  CAS  PubMed  PubMed Central  Google Scholar 

Geng J, Bao H, Chen Y, Shi L, Geng J, Wang Q, Yu H (2020) Nucleos(t)ide analogues for the treatment of chronic hepatitis B: a systematic review with network meta-analysis. Expert Rev Anti Infect Ther 18(8):823–834. https://doi.org/10.1080/14787210.2020.1760843

Article  CAS  PubMed  Google Scholar 

Chen L, Cheng C, Chen B, Zhao Y, Zhang J, Wang B (2016) Cumulative incidence and risk factors of creatine kinase elevation associated with telbivudine. Eur J Clin Pharmacol 72(2):235–241. https://doi.org/10.1007/s00228-015-1978-9

Article  CAS  PubMed  Google Scholar 

Gane EJ, Wang Y, Liaw YF, Hou J, Thongsawat S, Wan M, Moon YM, Jia J, Chao YC, Niu J, Leung N, Samuel D, Hsu CW, Bao W, Lopez P, Avila C (2011) Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B. Liver Int 31(5):676–684. https://doi.org/10.1111/j.1478-3231.2011.02490.x

Article  CAS  PubMed  Google Scholar 

Ambang T, Tan JS, Ong S, Wong KT, Goh KJ (2016) Clinicopathological features of telbivudine-associated myopathy. PLoS ONE 11(9):e0162760. https://doi.org/10.1371/journal.pone.0162760

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ying Y, Hu YK, Jin JL, Zhang JM, Zhang WH, Huang YX (2018) Case report: lactic acidosis and rhabdomyolysis during telbivudine and tenofovir treatment for chronic hepatitis B. BMC Gastroenterol 18(1):45. https://doi.org/10.1186/s12876-018-0773-3

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zou XJ, Jiang XQ, Tian DY (2011) Clinical features and risk factors of creatine kinase elevations and myopathy associated with telbivudine. J Viral Hepat 18(12):892–896. https://doi.org/10.1111/j.1365-2893.2010.01412.x

Article  CAS  PubMed  Google Scholar 

Zhang XS, Jin R, Zhang SB, Tao ML (2008) Clinical features of adverse reactions associated with telbivudine. World J Gastroenterol 14(22):3549–3553. https://doi.org/10.3748/wjg.14.3549

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lan MY, Lin HC, Hu TH, Chen SF, Chen CH, Chang YY, Chiu KW, Lin TK, Chen SS (2023) Telbivudine-induced myopathy: clinical features, histopathological characteristics, and risk factors. J Clin Neurol 19(1):52–59. https://doi.org/10.3988/jcn.2023.19.1.52

Article  PubMed  PubMed Central  Google Scholar 

Zhou XJ, Lim SG, Lloyd DM, Chao GC, Brown NA, Lai CL (2006) Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: pharmacodynamic implications. Antimicrob Agents Chemother 50(3):874–879. https://doi.org/10.1128/AAC.50.3.874-879.2006

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yin X, Jiang K, Zhou Z, Yu H, Yan D, He X, Yan S (2023) Prognostic and immunological potential of ribonucleotide reductase subunits in liver cancer. Oxid Med Cell Longev 2023:3878796. https://doi.org/10.1155/2023/3878796

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lopez-Gomez C, Sanchez-Quintero MJ, Lee EJ, Kleiner G, Tadesse S, Xie J, Akman HO, Gao G, Hirano M (2021) Synergistic deoxynucleoside and gene therapies for thymidine kinase 2 deficiency. Ann Neurol 90(4):640–652. https://doi.org/10.1002/ana.26185

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lacombe ML, Lamarche F, De Wever O, Padilla-Benavides T, Carlson A, Khan I, Huna A, Vacher S, Calmel C, Desbourdes C et al (2021) The mitochondrially-localized nucleoside diphosphate kinase D (NME4) is a novel metastasis suppressor. BMC Biol 19(1):228. https://doi.org/10.1186/s12915-021-01155-5

Article  CAS  PubMed  PubMed Central  Google Scholar 

Long J, Wang M, Chen B, Zhang J, Wang B (2017) Chronic hepatitis B a critical discussion. Future Virol 12(3):111–117. https://doi.org/10.2217/FVL-2016-0094

Article  CAS  Google Scholar 

Li DY, Yin WJ, Yi YH, Zhang BK, Zhao J, Zhu CN, Ma RR, Zhou LY, Xie YL, Wang JL, Zuo SR, Liu K, Hu C, Zhou G, Zuo XC (2019) Development and validation of a more accurate estimating equation for glomerular filtration rate in a Chinese population. Kidney Int 95(3):636–646. https://doi.org/10.1016/j.kint.2018.10.019

Article  PubMed  Google Scholar 

Chen B, Chen L, Cheng C, Zhong M, Shi X, Zhang J, Wang B (2018) Determination of telbivudine in the plasma of chronic hepatitis B patients in long-term treatment by high-performance liquid chromatographic-tandem mass spectrometry. Biomed Chromatogr 32(4):e4140. https://doi.org/10.1002/bmc.4140

Article  CAS  Google Scholar 

Shi YY, He L (2005) SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 15(2):97–98. https://doi.org/10.1038/sj.cr.7290272

Article  CAS  PubMed  Google Scholar 

Zhou XJ, Ke J, Sallas WM, Farrell C, Mayers DL, Pentikis HS (2009) Population pharmacokinetics of telbivudine and determination of dose adjustment for patients with renal impairment. J Clin Pharmacol 49(6):725–734. https://doi.org/10.1177/0091270009333555

Article  CAS  PubMed  Google Scholar 

Fleischer RD, Lok AS (2009) Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. J Hepatol 51(4):787–791. https://doi.org/10.1016/j.jhep.2009.06.011

Article  CAS  PubMed  Google Scholar 

McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y, Savarese B, Kleiner D, Tsokos M, Luciano C et al (1995) Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 333(17):1099–1105. https://doi.org/10.1056/NEJM199510263331702

Article  CAS  PubMed  Google Scholar 

Xu H, Wang Z, Zheng L, Zhang W, Lv H, Jin S, Yuan Y (2014) Lamivudine/telbivudine-associated neuromyopathy: neurogenic damage, mitochondrial dysfunction and mitochondrial DNA depletion. J Clin Pathol 67(11):999–1005. https://doi.org/10.1136/jclinpath-2013-202069

Article  CAS  PubMed  Google Scholar 

Yu W, Li Z, Wu W, Zhao D, Yan C, Lin P (2023) Insights into the mechanisms of telbivudine-induced myopathy associated with mitochondrial dysfunction. Chem Biol Interact 383:110692. https://doi.org/10.1016/j.cbi.2023.110692

Article  CAS  PubMed  Google Scholar 

Orsucci D, Caldarazzo Ienco E, Rossi A, Siciliano G, Mancuso M (2021) Mitochondrial syndromes revisited. J Clin Med 10(6):1249. https://doi.org/10.3390/jcm10061249

Article  CAS  Google Scholar 

Jianfei L, Min W, Chunlai M, Bicui C, Jiming Z, Bin W (2017) The Ca2+/CaMKK2 axis mediates the telbivudine induced upregulation of creatine kinase: implications for mechanism of antiviral nucleoside analogs’ side effect. Biochem Pharmacol 146:224–232. https://doi.org/10.1016/j.bcp.2017.10.005

Article  CAS  PubMed